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Summary
Activation of CDK1 is essential for M-phase entry both in
mitosis and meiosis. G2-arrested oocytes contain a pool
of CDK1/cyclin B complexes that are maintained inactive
because of the phosphorylation of CDK1 on Thr14 and
Tyr15 by the Wee1 family protein kinase Myt1, whose inhibi-
tion suffices to induce meiosis I entry [1–5]. CDK1/XRINGO
and p90Rsk can both phosphorylate and downregulate
Myt1 activity in vitro [6, 7]. Here we identify five p90Rsk
phosphorylation sites on Myt1 that are different from the
CDK1/XRINGO sites, and we show how both kinases syner-
gize during oocyte maturation to inhibit Myt1, ensuring
meiotic progression. We found that phosphorylation of
Myt1 by CDK1/XRINGO early during oocyte maturation not
only downregulates Myt1 kinase activity but also facilitates
the recruitment of p90Rsk and further phosphorylation of
Myt1. Mutation of the five p90Rsk residues to alanine impairs
Myt1 hyperphosphorylation during oocyte maturation and
makes Myt1 resistant to the inhibition by p90Rsk. Impor-
tantly, Myt1 phosphorylated by p90Rsk does not interact
with CDK1/cyclin B, ensuring that the inhibitory phosphory-
lations of CDK1 cannot take place after meiosis I entry and
contributing to the all-or-none meiotic response.
Results and Discussion
Myt1 is thought to play an important role in the G2 arrest of
Xenopus oocytes [5, 8, 9]. The activity of Myt1 appears to be
cell-cycle regulated because it is lower in M phase, which
correlates with its hyperphosphorylation [8–11]. The phos-
phorylation of Myt1 by XRINGO-activated CDK1 results in
Myt1 inhibition [7]. This observation, together with the accu-
mulation of XRINGO protein early during oocyte maturation
[12], suggests that XRINGO plays a triggering role in meiotic
G2-M progression. However, XRINGO antisense oligonucleo-
tides delay but do not block progesterone-induced oocyte
maturation [13], indicating that additional kinases are probably
implicated in Myt1 inactivation. An excellent candidate is the
p42MAPK-activated protein kinase p90Rsk, which can inter-
act with and phosphorylate Myt1, inhibiting its activity [6].
Moreover, interfering with the activation of the p90Rsk path-
way has been shown to delay meiosis I entry [14–17].
Myt1 contains two domains, the N-terminal kinase domain
and the C-terminal (Ct) regulatory domain, separated by a
putative membrane-anchor region [8, 9, 11] (see Figure S1A
available online). Overexpression of full-length Myt1 delayed
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Carlos III, Majadahonda 28220, Spainwhereas the oocytes injected with Myt1-DC, which lacks the
last 210 Ct residues but retains the catalytic domain, matured
with similar kinetics as mock-injected oocytes (Figure S1B).
Moreover, the electrophoretic mobility of Myt1-DC was not
retarded, suggesting that it was not hyperphosphorylated, in
spite of the activation of both maturation promoting factor
(MPF) and the p42MAPK pathway (Figure S1C). We confirmed
that full-length Myt1 and Myt1-DC had similar kinase activities
(Figure S1D), suggesting that the impaired recruitment of
CDK1/cyclin B to Myt1-DC was probably responsible for its
reduced ability to inhibit oocyte maturation. Taken together,
these results indicate that the Ct domain is necessary for the
Myt1 inhibitory function during oocyte maturation.
To test whether p90Rsk and CDK/XRINGO phosphorylate
Myt1-Ct on different sites, we used the 3AP mutant (Figure 1A),
with the three CDK/XRINGO phosphorylation sites (Ser410,
Ser414, and Ser444) changed to Ala [7], as a substrate in
kinase assays. Interestingly, p90Rsk phosphorylated Myt1-
Ct 3AP with similar efficiency as wild-type (WT) Myt1-Ct
(Figure 1B). Moreover, upon phosphorylation by p90Rsk, full-
length WT Myt1 and Myt1-3AP proteins were both less effi-
cient at inhibiting CDK1/cyclin B activity, indicating that
p90Rsk also inactivated Myt1-3AP (Figure 1C).
Xenopus Myt1-Ct contains seven putative consensus
p90Rsk phosphorylation sites, which are preceded by N-ter-
minal Arg residues (Figure S1E). Using several GST-fused
Myt1-Ct fragments, we found that residues Ser515 and
Ser517 did not significantly contribute to Myt1 phosphoryla-
tion. Therefore, we systematically mutated to Ala the rest of
the putative p90Rsk phosphorylation sites in Myt1-Ct. We
found that mutation of Thr453 (TA mutant) had no effect on
Myt1-Ct phosphorylation by p90Rsk. In contrast, the mutation
of Ser472 and Ser475 (2A mutant) reduced the phosphorylation
of Myt1-Ct by about 25%. Interestingly, the combined muta-
tion of T453A, S472A, and S475A (2A+TA mutant) reduced the
phosphorylation of Myt1-Ct by p90Rsk about 70% compared
with WT Myt1-Ct. Additional mutation of Ser492 (3A mutant)
and Ser504 (4A mutant), in combination with S472A and
S475A, further reduced the phosphorylation of Myt1-Ct by
p90Rsk to about 60% and 80%, respectively (Figure 1D).
Finally, combination of the five mutations (5A mutant) almost
completely abrogated Myt1-Ct phosphorylation by p90Rsk
(Figures 1D and 1E), suggesting that they all contribute to the
phosphorylation of Myt1 by p90Rsk. In contrast, CDK1/
XRINGO phosphorylated Myt1-Ct 5A as efficiently as WT
Myt1-Ct (Figure 1E).
Importantly, the Myt1-Ct 5A mutant was phosphorylated to
a lesser extent than WT Myt1 in progesterone-stimulated
oocytes (Figure 1F). In particular, the late Myt1 phosphoryla-
tion was delayed and reduced, and we did not observe the
marked upshift of Myt1 at meiosis I entry, in spite of the normal
activation of both MPF and the p42MAPK-p90Rsk pathway
(Figure 1F). These results implicate Thr453, Ser472, Ser475,
Ser492, and Ser504 in the late phosphorylation of Myt1 during
M phase. We also used a commercial antibody that recognizes
phospho-Ser/Thr in the sequence RXRXXS*/T* to follow the
phosphorylation of Myt1 during oocyte maturation. We con-
firmed that this antibody recognized p90Rsk-phosphorylated
Figure 1. Identification of p90Rsk Phosphorylation Sites in the Regulatory Domain of Myt1
(A) Summary of the Myt1 mutants used in this study and their designations.
(B) Kinase assays were performed with CDK1/XRINGO complexes (200 ng each) or with recombinant p90Rsk (300 ng) with wild-type (WT) GST-Myt1-Ct
or the mutant 3AP as substrates (2 mg) in the presence of [g-32P]ATP for 15 min at 30C. Myt1 phosphorylation was visualized by autoradiography.
(C) Myc-tagged full-length Myt1 proteins (WT or mutant 3AP) were expressed in reticulocyte lysates and immunoprecipitated and incubated with recombi-
nant p90Rsk (900 ng) in the presence of ATP at 30C. After 60 min, the Myt1 immunoprecipitates were recovered and washed extensively. The immunopuri-
fied Myt1 was further incubated in the presence of recombinant CDK1-cyclin B1-Cak1/Civ1 (120 ng) for 30 min before H1K assays were performed.
(D and E) Kinase assays were performed with CDK1/XRINGO (200 ng each) or recombinant p90Rsk (300 ng) and GST-Myt1-Ct WT or mutant proteins (2 mg),
as indicated, in the presence of [g-32P]ATP for 30 min at 30C. Myt1 phosphorylation was visualized by autoradiography.
(F) Xenopus oocytes were injected with Myc-tagged Myt1-Ct, either WT or the mutants 3AP, 5A, or 8A, incubated for 14 hr at 18C, and then stimulated
with progesterone. Oocytes were collected at the indicated times after progesterone stimulation, and lysates were assayed for H1K activity or analyzed
by immunoblotting. Myt1-Ct was detected with Myc antibody. To detect Myt1 phosphorylation, we immunoprecipitated oocyte lysates with Myc antibody
and then analyzed them by immunoblotting with a phospho-Ser/Thr antibody that recognizes the sequences RXRXXS*/T* (phospho-S/T). Molecular weights
are indicated in kDa.
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718Myt1, in addition to the CDK-phosphorylated sites Ser410 and
Ser414, which are both preceded by Arg residues (Figures S1F
and S1G). We found that this antibody detected an early (3 hr)
and a late (6–12 hr) Myt1 phosphorylation in progesterone-
treated oocytes that both correlated with slower electropho-
retic migration of Myt1 (Figure 1F). However, we could not
detect any phosphorylation of Myt1-3AP with the same anti-
body. In contrast, Myt1-5A was phosphorylated at early but
not at late times, suggesting that the CDK/XRINGO sites
were only transiently phosphorylated. Finally, when the CDK/
XRINGO and p90Rsk sites were all mutated to Ala (Myt1-8A),
we could not detect any Myt1 phosphorylation with this anti-
body. Of note, the Myt1-8A mutant was still slightly upshiftedat late times (Figure 1F), suggesting that additional Myt1 sites
might be phosphorylated in mature oocytes.
To understand the biological significance of Myt1 phosphor-
ylation by p90Rsk, we generated a mutant version of full-length
Myt1 in which the five p90Rsk sites were changed to either
Ala (Myt1-5A) or Asp (Myt1-5D). Overexpression of WT Myt1
delayed the kinetics of meiosis I entry induced by proges-
terone, and a stronger effect was observed upon expression
of Myt1-5A. In contrast, the oocytes injected with Myt1-5D
matured with similar kinetics, albeit a bit slower, than mock-
injected oocytes, indicating that Myt1-5D was less efficient
at inhibiting progesterone-induced oocyte maturation (Fig-
ure S2A). Consistent with these results, dephosphorylation of
Figure 2. Phosphorylation and Inhibition of Myt1 by p90Rsk
(A) Xenopus oocytes were injected with 10 ng of mRNA-encoding Myc-tagged full-length Myt1, either WT or the mutants 3AP, 5A, and 8A, or with water as
a control, incubated for 14 hr at 18C, and then stimulated with progesterone. Germinal vesicle breakdown (GVBD) was scored every hour.
(B)Xenopus oocytes were injected as in (A) and collected at the indicated times after progesterone stimulation, and the lysates were assayed for H1K activity
or analyzed by immunoblotting. Myt1 was detected with Myc antibody.
(C) Myc-tagged full-length Myt1 proteins (WT or mutants 5A and 5D) were expressed in reticulocyte lysates, immunoprecipitated with Myc antibodies, and
then incubated with recombinant CDK1-cyclin B1-Cak1/Civ1 (120 ng) for 30 min before performing H1K assays.
(D) Myc-tagged full-length Myt1 proteins (WT or mutant 5A) were expressed in reticulocyte lysates and immunoprecipitated and preincubated with p90Rsk
(900 ng) or CDK1/XRINGO (800 ng) in the presence of ATP at 30C. After 45 min, the Myt1 immunoprecipitates were recovered and washed extensively. The
immunopurified Myt1 was further incubated in the presence or absence of recombinant CDK1-cyclin B1-Cak1/Civ1 (120 ng) for 30 min at 30C before H1K
assays were performed. The two right lanes show the controls with immunopurified Myt1 preincubated with p90Rsk or CDK1/XRINGO but directly assayed
for H1K activity, in the absence of CDK1/cyclin B1.
(E) Myc-tagged full-length Myt1 proteins were expressed in reticulocyte lysates and immunoprecipitated and incubated with recombinant p90Rsk (900 ng)
for 45 min in the presence of [g-32P]ATP.
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719the inhibitory Thr14 and Tyr15 sites of endogenous CDK1 and
activation of CDK1/cyclin B were both slower in the oocytes
expressing WT Myt1 or Myt1-5A than in oocytes expressing
Myt1-5D (Figure S2B). Taken together, these results suggest
that phosphorylation of these five residues interferes with
the inhibitory role of Myt1 in oocyte maturation. When differ-
ent nonphosphorylatable Myt1 mutants were compared, we
observed that overexpression of Myt1-3AP or Myt1-8A had
an even stronger effect than Myt1-5A at delaying the kinetics
of meiosis I entry (Figure 2A), which correlated with both slower
dephosphorylation of CDK1 on Thr14 and Tyr15 and CDK1/
cyclin B activation in those oocytes (Figure 2B).
Next, we confirmed that phosphorylation by full-length WT
Myt1 or Myt1-5A effectively inhibited the kinase activity of
CDK1/cyclin B in vitro (Figure 2C). In contrast, Myt1-5D was
less efficient and only partially reduced CDK1/cyclin B activity
(to about 40%), which was consistent with the reduced ability
of this mutant to inhibit progesterone-induced oocyte matura-
tion (Figure S2A). These results suggest that phosphorylationof the five p90Rsk sites regulates the ability of Myt1 to inhibit
CDK1/cyclin B kinase activity. In support of this idea, incuba-
tion with recombinant active p90Rsk significantly inhibited WT
Myt1 but did not affect the ability of Myt1-5A to inactivate
CDK1/cyclin B (Figure 2D; Figure S2C), in agreement with
the phosphorylation of WT Myt1 but not Myt1-5A by p90Rsk
(Figure 2E). On the other hand, CDK1/XRINGO inhibited
the kinase activities of WT Myt1 and Myt1-5A with similar effi-
ciencies (Figure 2D). Taken together, these results indicate
that p90Rsk and CDK1/XRINGO phosphorylate Myt1-Ct on
different sites and probably represent parallel pathways lead-
ing to Myt1 inactivation.
To determine whether Myt1 phosphorylation by CDK1/
XRINGO regulates its interaction with p90Rsk, we incubated
either GST-Myt1-Ct WT or the mutants that contain the three
CDK/XRINGO phosphorylation sites changed to Ala (Myt1-
3AP) or to Asp (Myt1-3DP) [7] in oocyte lysates and then
performed GST pull-down assays to analyze the binding of
endogenous p90Rsk. In agreement with previous results [6],
Figure 3. Reduced Ability of the Myt1-5D Mutant to Bind to CDK1/Cyclin B
(A) Xenopus oocytes were incubated or not with progesterone for 12 hr. GST-Myt1-Ct proteins (5 mg), either WT or the mutants 3AP and 3DP, as well as
glutathione S-transferase (GST) (5 mg) as a negative control, were incubated with lysates prepared from G2-arrested or progesterone-matured oocytes
during 3 hr at 4C. GST pull downs were analyzed by immunoblotting with p90Rsk1, p90Rsk2, or GST antibodies. An aliquot of the total lysates (TL) was
also analyzed by immunoblotting.
(B) GST-Myt1-Ct proteins (6 mg), either WT or the indicated mutants (designated as in Figure 1A but changed to either Asp or Ala), were incubated with
lysates from G2-arrested oocytes during 3 hr at 4C. GST pull downs were analyzed by immunoblotting with CDK1, cyclin B2, and GST antibodies. The upper
CDK1 band corresponds to cyclin B-bound CDK1 phosphorylated on Thr14 and Tyr15.
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720we observed that Myt1-Ct associated with the active and
hyperphosphorylated p90Rsk1 and p90Rsk2 present in mature
oocytes, but not with the inactive and underphosphorylated
p90Rsk forms present in G2-arrested oocytes (Figure 3A).
Interestingly, the nonphosphorylatable mutant Myt1-3AP inter-
acted less efficiently with both p90Rsk family members than
WT Myt1, whereas the phosphomimetic mutant Myt1-3DP
was able to bind more efficiently to p90Rsk1 and p90Rsk2
(Figure 3A). These results suggest that the phosphorylation of
Ser410, Ser414, and Ser444 by CDK1/XRINGO facilitates the
binding of p90Rsk to Myt1-Ct.
Next, we addressed how p90Rsk phosphorylation impaired
Myt1 activity. Previous work has shown that the Ct domain of
Myt1 is involved in the recruitment of CDK1/cyclin B through
an RXL motif that binds to cyclin B [8, 9]. In contrast, we found
that RXL was not required for the binding of Myt1 to XRINGO
(Figure S3A). To determine whether Myt1 phosphorylation
affected its interaction with CDK1/cyclin B, we analyzed the
binding of different GST-Myt1-Ct phosphorylation mutants to
the endogenous CDK1 from oocyte lysates. We found that
the majority of the CDK1 that associated with Myt1 probably
corresponded to cyclin B-bound CDK1, which is phosphory-
lated on Thr14 and Tyr15 (Figure 3B). Interestingly, the only
Myt1 mutant that was impaired in CDK1 binding was Myt1-
5D, suggesting that the sites phosphorylated by p90Rsk
regulate the interaction between Myt1-Ct and CDK1. Further
analysis indicated that Myt1-Ct needs to be phosphorylated
by p90Rsk in at least four residues to release CDK1/cyclin B
(Figure 3B). Previous studies have shown that Myt1 only phos-
phorylates CDK1 when it is bound to cyclin B [18], and weconfirmed that endogenous cyclin B2 coprecipitated with
CDK1 in the GST-Myt1 pull downs (Figure 3B). These results
are in agreement with previous work [8], suggesting that the
phosphorylation status of Myt1 regulates its binding to
CDK1/cyclin B.
We also investigated whether p90Rsk could downregulate
Myt1 catalytic activity. As shown above (Figure 2C), Myt1-5D
was less effective than Myt1-WT at inactivating CDK1/cyclin
B in vitro. However, we found no obvious differences in Myt1
autophosphorylation, as a reporter of kinase activity [19],
between Myt1-5D and WT Myt1 (Figure S3B), suggesting
that p90Rsk phosphorylation might have a small effect on
Myt1 kinase activity. In contrast, the autophosphorylation
ability of Myt1-3DP was significantly impaired, suggesting
that CDK1/XRINGO phosphorylation inhibits Myt1 kinase
activity, in agreement with previous work [7]. Moreover, incu-
bation with Myt1-Ct 3DP, but not with the WT protein, inhibited
full-length Myt1 autophosphorylation (Figure S3C), suggesting
that direct interaction between the CDK1/XRINGO phosphory-
lated Ct residues and the catalytic domain of Myt1 may inhibit
its kinase activity.
To further understand the regulation of Myt1 during oocyte
maturation, we expressed several phosphorylation mutants
in oocytes, which were then treated with progesterone, and
assayed the kinase activities of the Myt1 mutants in immuno-
precipitates (Figure 4A). We found that the WT, 3AP, 5A,
and 8A Myt1 proteins were all able to inactivate CDK1/cyclin
B in vitro. However, during the G2-M transition, WT Myt1
was partially inactivated, which correlated with its phosphory-
lation by CDK1/XRINGO (see Figure 1F), whereas Myt1-3AP
Figure 4. Regulation of Myt1 Activity during Oocyte Maturation
(A) Xenopus oocytes were injected with 10 ng of mRNAs encoding Myc-tagged full-length Myt1, either WT or the mutants 3AP, 5A, and 8A, or with water
as a control, incubated 14 hr at 18C, and then stimulated with progesterone. Oocytes were collected before progesterone stimulation (G2-phase) and
4 hr (G2-M transition) or 12 hr (M-phase) after progesterone stimulation. Myt1 proteins were immunoprecipitated with Myc antibody and analyzed by immu-
noblotting with Myc and CDK1 antibodies or were incubated with recombinant CDK1-cyclin B1-Cak1/Civ1 (100 ng) for 60 min before H1K assays were
performed.
(B) Model for the proposed interplay between CDK1/XRINGO and p90Rsk in the regulation of Myt1 and CDK1/cyclin B activation during oocyte maturation.
See Results and Discussion for details.
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721remained active. Myt1-5A was also transiently inactivated, and
Myt1-8A behaved similarly to Myt1-3AP. At later times, when
the majority of mock-injected oocytes had entered meiosis I,
Myt1-WT was fully phosphorylated and inactivated (Fig-
ure 4A). Myt1-3AP remained active because it was phosphor-
ylated by neither CDK1/XRINGO nor p90Rsk, which cannot be
recruited to Myt1 in the absence of CDK1/XRINGO phosphor-
ylation. Myt1-5A also remained active, consistent with the lack
of phosphorylation on CDK1/XRINGO sites because of the
transient nature of these phosphorylations (Figure 1F). As
expected, Myt1-8A was also active as a result of the lack of
phosphorylation by both CDK1/XRINGO and p90Rsk. It should
be noted that because of the small percentage of oocytes
injected with Myt1-8A that matured upon progesterone stimu-
lation (see Figure 2A), it is difficult to know whether Myt1-8A
could be inactivated in mature oocytes by CDK1/XRINGO
and p90Rsk-independent mechanisms.
We also analyzed the binding of the different Myt1 mutants
to endogenous CDK1 and found that underphosphorylated
Myt1 was constitutively bound to CDK1 in G2 oocytes(Figure 4A). When oocytes entered M phase, only Myt1-WT
released CDK1. However, Myt1-3AP, which cannot be phos-
phorylated by CDK1/XRINGO and does not recruit p90Rsk,
as well as Myt1-5A and Myt1-8A, which both have the
p90Rsk phosphorylation sites mutated, all remained bound
to CDK1 (Figure 4A). We conclude that Myt1 is first transiently
phosphorylated by CDK1/XRINGO and partially inactivated,
and then p90Rsk is recruited and phosphorylates five addi-
tional sites, inducing the release of CDK1/cyclin B from
Myt1, which allows full CDK1/cyclin B activation.
Our results indicate that XRINGO and p90Rsk are both
required for the correct timing of MPF activation and meiosis
I entry in oocytes. We propose the following sequence of
events during oocyte maturation (Figure 4B). In G2-arrested
oocytes, Myt1 is active, and stimulation with progesterone
induces the early accumulation of XRINGO protein [12], which
binds to and activates monomeric CDK1. The CDK1/XRINGO
complex phosphorylates Myt1 on three Ser residues, downre-
gulating its catalytic activity. This inhibition is probably medi-
ated by the interaction between the phosphorylated Ct and
Current Biology Vol 20 No 8
722the kinase domain of Myt1. The p90Rsk pathway also
becomes activated in maturing oocytes, albeit later than
XRINGO accumulation, and active p90Rsk is recruited to
CDK1/XRINGO-phosphorylated Myt1. CDK1/XRINGO phos-
phorylation might not be absolutely required for the phosphor-
ylation of Myt1 by p90Rsk, although the phosphorylated sites
probably facilitate Myt1-p90Rsk association. Then p90Rsk
phosphorylates five residues on Myt1, which interfere with
its binding to CDK1/cyclin B, maybe by electrostatic repulsion
or by changing the Myt1 protein conformation, facilitating the
activation of CDK1/cyclin B by Cdc25-mediated dephosphor-
ylation. This mechanism resembles the role of p90Rsk in the
modulation of Emi2 activity during meiosis II arrest. In that
case, p90Rsk binds to CDK-phosphorylated Emi2 and further
phosphorylates Emi2, promoting the recruitment of PP2A,
which then dephosphorylates Emi2 sites that control binding
to the anaphase-promoting complex/cyclosome [20].
The reduced affinity of p90Rsk-phosphorylated Myt1 for
CDK1/cyclin B should also contribute to the irreversibility of
MPF activation. In particular, cyclin B synthesis is strongly
upregulated during oocyte maturation [21], and the newly
formed CDK1/cyclin B complexes would not be inhibited by
Myt1, ensuring the generation of optimal levels of MPF activity
required to drive meiotic progression.
Experimental Procedures
Oocyte Maturation and mRNA Expression
Xenopus oocytes were obtained from primed frogs, and meiotic maturation
was induced by incubation of manually dissected oocytes with 5 mg/ml
(15 mM) of progesterone (Sigma) and was scored by the appearance of
a white spot at the animal pole of the oocytes, which indicates germinal
vesicle breakdown and meiosis I entry. For expression of Myc-tagged
proteins, oocytes were microinjected with 50 nl of in vitro transcribed
mRNAs (mMessage mMachine kit, Ambion) and maintained overnight in
modified Barth’s medium at 18C before progesterone treatment. For the
preparation of lysates, oocytes were homogenized in 10 ml per oocyte of
ice-cold H1K buffer (80 mM b-glycerophosphate, pH 7.5, 20 mM EGTA,
15 mM MgCl2, 1 mM DTT, 1 mM AEBSF, 2.5 mM Benzamidine, and 10 mg/ml
each of Aprotinin and Leupeptin). The lysates were centrifuged at 10,0003 g
for 10 min, and the cleared supernatants were stored at 270C.
Myt1 Kinase Activity Assays
Myt1 kinase assays were performed exactly as described [7], by incubating
Myc-tagged Myt1 proteins immunoprecipitated from microsomal mem-
brane-supplemented reticulocyte lysates with recombinant coexpressed
CDK1-cyclin B1-Cak1/Civ1 and histone H1. Samples were analyzed by
SDS polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography.
To determine the effect of XRINGO-activated CDK1 on Myt1 kinase
activity, we preincubated the immunoprecipitated Myt1 with active
recombinant CDK1/XRINGO for 45 min at room temperature (RT) in 30 ml
of H1K buffer supplemented with 350 mM ATP and then washed it at least
three times with H1K buffer before incubation with the CDK1/cyclin B1
substrate. To determine the effect of p90Rsk phosphorylation on Myt1
activity, we preincubated the Myt1 immunocomplexes with recombinant
active p90Rsk-EE [22] for 45 min at RT in 30 ml of S6 kinase buffer (50 mM
MOPS [pH 7.2], 1 mM DTT, 10 mM MgCl2, 10 mM p-nitrophenylphosphate,
1 mM NaVO3, 10 mg/ml Leupeptin, 10 mg/ml Aprotinin, 100 mM PMSF or
AEBSF) supplemented with 350 mM ATP and then washed them at least
three times with H1K buffer before incubation with CDK1/cyclin B1.
Myt1 autophosphorylation was assayed by directly incubating the bead-
bound Myt1 immunocomplexes with H1K buffer containing 8 mCi of
[g-32P]ATP for 2 hr at 30C. Samples were finally boiled in sample buffer
and analyzed by SDS-PAGE and autoradiography.
The effect of the Ct domain on Myt1 catalytic activity was determined by
preincubating the bead-bound Myt1 immunocomplexes with GST-Myt1-Ct
either WT or mutant 3DP at RT. After 30 min, Myt1 autophosphorylation was
assayed as above.
To assay the activity of Myt1 proteins expressed in Xenopus oocytes, we
immunoprecipitated Myc-tagged Myt1 proteins as described [6] with 10 mlof Myc beads. After 3 hr, the bead-bound Myt1 immunocomplexes were
washed three times in IP buffer and twice with H1K buffer and then
incubated in 20 ml of kinase buffer containing 350 mM ATP and 120 ng of
recombinant coexpressed CDK1-cyclin B1-Cak1/Civ1. After 60 min at RT,
the CDK1/cyclin B1 activity was assayed with 4 mg of histone H1 and
2 mCi of [g-32P]ATP for 15 min at 30C. Samples were finally boiled in sample
buffer and analyzed by SDS-PAGE and autoradiography.
For quantifications, we used a Phosphorimager (Storm 820, Molecular
Dynamics) to collect radioactive emissions; computer images were analyzed
with the volume integration method of the ImageQuant software.
Supplemental Information
Supplemental Information includes Supplemental Experimental Procedures
and three figures and can be found with this article online at doi:10.1016/j.
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